Name of this trial: ELAINE 3
What type of cancer is this for? BREAST
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer that has spread to other parts of the body.
What biomarkers are involved? You must have estrogen receptor positive, HER2 negative Breast Cancer with an ESR1 Mutation
What is National Clinical Trial #? NCT05696626
Brief summary of trial: This trial compares how effective and safe the combination of Lasofoxifene and Abemaciclib is, compared to the combination of Fulvestrant and Abemaciclib. Lasofoxifene and Abemaciclib are both pills, and Fulvestrant is an injection.
Need to know: You must have tried Ribociclib or palbociclib-based treatment before.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name: SERENA 6
What type of cancer is this for? BREAST
Phase: III
Who is this trial for? Men and women with Breast Cancer that has spread to other parts of the body.
What biomarkers are involved? You must be hormone receptor (HR) positive, HER2 negative and have a positive ESR1 mutation
What is National Clinical Trial #? NCT04964934
Brief summary of trial: This trial looks to see how well AZD9833 (the drug that is being studied) plus palbociclib or abemaciclib works compared to either anastrozole or letrozole plus palbociclib or abemaciclib.
Need to know: You must have tried either anastrozole or letrozole plus a CDK4/6 inhibitor (Abemaciclib, Palbociclib or Ribociclib)
Where is this trial available?: The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial? BEGONIA
What type of cancer is this for? BREAST
Phase of this trial? Phase II
Who is this trial for? Men and Women with breast Cancer that has spread to other parts of the body.
What biomarkers are involved? You must have estrogen receptor negative, progesterone receptor negative and HER2 negative breast cancer.
What is the National Clinical Trial #? NCT03742102
Brief summary of trial: This trial is looking to see how safe and well-tolerated Durvalumab and datopotamab deruxtecan are.
Need to know: You can have had treatment for your breast cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: GILEAD ASCENT-05
What type of cancer is this for? BREAST Cancer Triple Negative
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer early stage not cured with chemotherapy and surgery.
What biomarkers are involved? You must have estrogen receptor negative, progesterone receptor negative, and HER2 negative Breast Cancer
What is National Clinical Trial #? NCT05633654
Brief summary of trial: This trial compares how effective and safe the combination of Sacituzumab Govitecan and Pembrolizumab is, compared to treatment of physician’s choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy.
Need to know: Must have had neoadjuvant treatment and surgery for breast surgery with residual disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com